Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week ...

The UK regulatory authorities have approved the first ever trial of a revolutionary gene therapy for young children diagnosed with Hunter syndrome ... also known as mucopolysaccharidosis type II (MPS ...

was approved in Japan for the treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). MPS II is a rare, inherited disorder caused by defects in iduronate-2-sulfatase (IDS), an enzyme ...

Denali remains on track to submit a BLA for tividenofusp alfa or DNL310 for the treatment of MPS II (Hunter syndrome), under the accelerated approval pathway in early 2025, and is preparing for a ...

Shire’s attempts to develop a drug for cognitive impairment from the rare inherited disease Hunter Syndrome has failed ... and families living with MPS II.” “We are grateful to the children ...

The University of Manchester has announced today a groundbreaking gene therapy partnership to ease the lifelong suffering of people with Hunter syndrome. The University has agreed to a worldwide ...